ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Peter Hillmen, Jennifer R Brown, Barbara F Eichhorst, Nicole Lamanna, Susan M O'Brien, Lugui Qiu, Tommi Salmi, James Hilger, Kenneth Wu, Aileen Cohen, Jane Huang, Constantine S Tam, Peter Hillmen, Jennifer R Brown, Barbara F Eichhorst, Nicole Lamanna, Susan M O'Brien, Lugui Qiu, Tommi Salmi, James Hilger, Kenneth Wu, Aileen Cohen, Jane Huang, Constantine S Tam
Abstract
Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.
Keywords: BTK inhibitor; Bruton tyrosine kinase; chronic lymphocytic leukemia; clinical trials; comparative effectiveness; hematologic/leukemia; ibrutinib; zanubrutinib.
Source: PubMed